The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Case study update: alpelisib for the treatment of PI3K-driven Langerhans cell histiocytosis
Roei Mazor
• 10 Jun 2022
Roei Mazor, MD, PhD, Assuta Medical Center, Tel Aviv, Israel, discusses a case study in which a patient with PI3K-driven Langerhans cell histiocytosis was treated with alpelisib. Dr Mazor first highlights driver mutations commonly found in this rare disease and then discusses the impressive results observed with the use of alpelisib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
